オプションチェーンは、Centeneの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Centeneの市場センチメントを評価します。.

Centene (NYSE:CNC) 株価情報, オプションチェーン

Centene

Centene is a managed care organization focused on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 24 million medical members as of September, mostly in Medicaid (about 60% of membership), the individual exchanges (about 20%), and Medicare Advantage (about 5%). The company also serves traditional Medicare users with its Medicare Part D pharmaceutical program and has a military contract.

Centene Corp

Canna Corp

CHINA NUCLEAR ENERGY TECH by CHINA NUCLEAR ENERGY TECHNOLOGY CORP LTD.

CANCER CAPITAL CORP by Cancer Capital Corp.

Cancer Capital Corp

CONNECTED MEDIA TECHS INC by Connected Media Technologies, Inc.

Connected Media Technologies Inc

CHUN CAN CAPITAL GROUP by Chun Can Capital Group

Chun Can Capital Group

Core Nickel Corp

CONDUIT CAPITAL LTD ORD by Conduit Capital Ltd.

Range Cancer Therapeutics ETF

CHINA CASTSON 81 FINCE by CHINA CASTSON 81 FINANCE CO.

CHINA TELETECH HLDGS INC by China Teletech Holding, Inc.

China Teletech Holding Inc

Centene's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) short percent of float has risen 3.57% since its last report. The company recently reported that it has 8.09 million shares sold short, which is 1.74% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.97 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Centene Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730812513_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Centene has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Centene's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Centene's peer group average for short interest as a percentage of float is 4.34%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

(CNC) - Analyzing Centene's Short Interest

Wells Fargo analyst Stephen Baxter maintains Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) with a Overweight and lowers the price target from $91 to $90.

News

Price Target

Analyst Ratings

Wells Fargo Maintains Overweight on Centene, Lowers Price Target to $90

<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4293554-1&amp;h=3420507561&amp;u=https%3A%2F%2Fwww.centene.com%2F&amp;a=Centene+Corporation">Centene Corporation</a>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>), a leading healthcare enterprise committed to helping people live healthier lives, announced today that its subsidiary, <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4293554-1&amp;h=1525079035&amp;u=https%3A%2F%2Fwww.buckeyehealthplan.com%2F&amp;a=Buckeye+Health+Plan">Buckeye Health Plan</a>&nbsp;(Buckeye), has been selected by the Ohio Department of Medicaid (ODM) to continue providing Medicare and Medicaid services for dually eligible individuals through a Fully Integrated Dual Eligible Special Needs Plan (FIDE SNP). FIDE SNPs fully integrate care for dually eligible beneficiaries under a single managed care organization, allowing enrollees to receive all of their medical, behavioral and long-term services and supports through one plan.

Biotech

General

Centene's Buckeye Health Plan Awarded Contract To Serve Dual Eligible Medicare And Medicaid Members In Ohio

Bernstein analyst Lance Wilkes maintains Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) with a Outperform and lowers the price target from $96 to $88.

Bernstein Maintains Outperform on Centene, Lowers Price Target to $88

Barclays analyst Andrew Mok maintains Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) with a Overweight and lowers the price target from $97 to $91.

Barclays Maintains Overweight on Centene, Lowers Price Target to $91

Investors with a lot of money to spend have taken a bearish stance on Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with CNC, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 14 uncommon options trades for Centene.
This isn't normal.
The overall sentiment of these big-money traders is split between 35% bullish and 64%, bearish.
Out of all of the special options we uncovered, 5 are puts, for a total amount of $164,810, and 9 are calls, for a total amount of $443,199.
<h3>Predicted Price Range</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $62.0 to $72.5 for Centene during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Centene's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Centene's substantial trades, within a strike price spectrum from $62.0 to $72.5 over the preceding 30 days.
<h3>Centene Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729886449_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CNC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$2.15</td>
<td>$2.05</td>
<td>$2.15</td>
<td>$67.50</td>
<td>$75.7K</td>
<td>526</td>
<td>815</td>
</tr>
<tr>
<td>CNC</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$6.6</td>
<td>$6.4</td>
<td>$6.55</td>
<td>$62.50</td>
<td>$64.1K</td>
<td>350</td>
<td>143</td>
</tr>
<tr>
<td>CNC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$6.1</td>
<td>$5.7</td>
<td>$5.75</td>
<td>$65.00</td>
<td>$59.4K</td>
<td>105.3K</td>
<td>513</td>
</tr>
<tr>
<td>CNC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$1.15</td>
<td>$1.0</td>
<td>$1.15</td>
<td>$72.50</td>
<td>$57.5K</td>
<td>1.2K</td>
<td>781</td>
</tr>
<tr>
<td>CNC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$1.0</td>
<td>$0.95</td>
<td>$1.0</td>
<td>$72.50</td>
<td>$46.1K</td>
<td>1.2K</td>
<td>1.6K</td>
</tr>
</tbody>
</table>

<h3>About Centene</h3>
Centene is a managed-care organization focused on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 24 million medical members as of June 2023, mostly in Medicaid (67% of membership), the individual exchanges (14%), and Medicare Advantage (6%) plans. The company also serves traditional Medicare users with its Medicare Part D pharmaceutical program.
In light of the recent options history for Centene, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Current Position of Centene</h3>
<ul>
<li>Trading volume stands at 9,607,957, with CNC's price up by 4.68%, positioned at $64.5.</li>
<li>RSI indicators show the stock to be may be approaching oversold.</li>
<li>Earnings announcement expected in 0 days.</li>
</ul>
<h3>Professional Analyst Ratings for Centene</h3>
A total of 2 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $78.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Overweight with a new price target of $90. 
&#x2A; Consistent in their evaluation, an analyst from Baird keeps a Neutral rating on Centene with a target price of $66. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Centene options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Markets

Centene Options Trading: A Deep Dive into Market Sentiment

Stocks are ending the week on a high note, with tech leading the charge as investors position ahead of next week&#8217;s pivotal earnings releases from <a href="https://www.benzinga.com/topic/magnificent-7">five of the &#8220;Magnificent Seven&#8221; stocks.</a>
Microsoft Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NYSE">MSFT</a>), Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), and Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) will all report quarterly earnings between Oct. 29 and Oct. 31.
Combined, nearly 45% of the S&amp;P 500 by market cap is set to report results next week, with other heavyweights including McDonald&#8217;s Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>), Visa Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>), Eli Lilly and Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), Mastercard Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>), Chevron Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>) and Exxon Mobil Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>).
Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) continued its upward trajectory on Friday, rising 2.7% following a massive 21% jump on Thursday — its biggest one-day gain since May 2013.
The S&amp;P 500 was up 0.5% at midday trading in New York, while the Nasdaq 100 surged by 1.5%, fueled by semiconductor stocks. 
The Dow Jones Industrial Average fell 0.3%, on track to end a six-week winning streak. The U.S. dollar strengthened further, with the DXY Index rising past the 104 mark, setting up for a fourth straight week of gains. Meanwhile, Treasury yields were steady. 
WTI crude rose 1.8%, driven by concerns over geopolitical tensions in the Middle East. Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) is up slightly at $67,695.
<h1 class="wp-block-heading">Friday&#8217;s Performance In Major U.S. Indices, ETFs</h1>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day % change</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>20,500.56</td>
<td>1.3%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,839.28</td>
<td>0.5%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,219.60</td>
<td>0.3%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>42,271.11</td>
<td>-0.3%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:50 p.m. ET</figcaption></figure>
According to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent102225&amp;t=be2bearmibe3na1">Benzinga Pro</a> data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 0.5% to $582.19.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;eased 0.2% to $423.18.</li>
<li>The tech-heavy Invesco QQQ Trust Series (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) rallied 1.3% to $498.83.</li>
<li>The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) inched 0.2% up to $220.09.</li>
<li>The Technology Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>) outperformed, up by 1.4%. The Utilities Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>) lagged, down 0.9%.</li>
</ul>
<h1 class="wp-block-heading">Thursday&#8217;s Stock Movers</h1>
<ul>
<li>Capital One Financial Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COF#NYSE">COF</a>) rallied 7% to levels last seen in October 2021 on better-than-expected quarterly results. </li>
<li>Digital Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLR#NYSE">DLR</a>) rallied over 10% after reporting record new lease bookings. </li>
</ul>
Other stocks reacting to earnings included:
<ul>
<li>Ameriprise Financial Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMP#NYSE">AMP</a>), down 0.13%</li>
<li>DexCom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>), down 1%</li>
<li>ResMed Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>) up 7.6%, </li>
<li>Skechers U.S.A. Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKX#NYSE">SKX</a>) down 0.2%, </li>
<li>Western Digital Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>) up 7.6%, </li>
<li>Deckers Outdoor Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>), up 11%</li>
<li>Edward Lifesciences Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>), down by 0.6%</li>
<li>HCA Healthcare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>), down 10%, </li>
<li>Aon plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AON#NYSE">AON</a>), up 6%, </li>
<li>Colgate-Palmolive Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>), down 3.4%, </li>
<li>Centene Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>), up 6.7%, </li>
<li>Saia Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIA#NASDAQ">SAIA</a>), up 9.2%. </li>
</ul>
Read Now:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41549147/goldman-sachs-analyst-remains-bullish-on-boeing-despite-weak-q3-long-term-deep-valu">Goldman Sachs Analyst Remains Bullish On Boeing Despite Weak Q3: &#8216;Long-Term Deep-Value Opportunity</a>&#8216;</li>
</ul>
Photo: Shutterstock

Earnings

Equities

Macro Economic Events

Sector ETFs

Broad U.S. Equity ETFs

Econ #s

Economics

Tech

ETFs

$BTC

AAPL

AMZN

DECK

SPDR Dow Jones Industrial Average ETF Trust

DXCM

GOOG

GOOGL

MSFT

RIVN

SAIA

TSLA

Select Sector SPDR-Consumer Discretionary

Tech Stocks Rally As Investors Await Magnificent 7 Earnings; Dollar Eyes Fourth Straight Positive Week: What's Driving Markets Friday?

Across the recent three months, 13 analysts have shared their insights on Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>), expressing a variety of opinions spanning from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $88.77, a high estimate of $98.00, and a low estimate of $66.00. This current average represents a 0.09% decrease from the previous average price target of $88.85. 
<img src="https://www.benzinga.com/files/images/story/2024/1729861241_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A comprehensive examination of how financial experts perceive Centene is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Ha</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$66.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$91.00</td>
<td>$93.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$97.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$98.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Scott Fidel</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$78.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$93.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>George Hill</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$87.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Gary Taylor</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$89.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Michael Wiederhorn</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$95.00</td>
<td>$110.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Centene. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Centene compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Centene's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into Centene's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CNC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Centene analyst ratings.</a>
<h2>Delving into Centene's Background</h2>
Centene is a managed-care organization focused on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 24 million medical members as of June 2023, mostly in Medicaid (67% of membership), the individual exchanges (14%), and Medicare Advantage (6%) plans. The company also serves traditional Medicare users with its Medicare Part D pharmaceutical program.
<h3>Unraveling the Financial Story of Centene</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Centene displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 5.92%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Centene's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 2.88%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Centene's ROE excels beyond industry benchmarks, reaching 4.22%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Centene's ROA stands out, surpassing industry averages. With an impressive ROA of 1.38%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Centene's debt-to-equity ratio surpasses industry norms, standing at 0.64. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>Analyst Ratings: What Are They?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Key Takeaways From Centene Analyst Ratings

Baird analyst Michael Ha maintains Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) with a Neutral and lowers the price target from $83 to $66.

Baird Maintains Neutral on Centene, Lowers Price Target to $66

<h3>Gainers</h3>
<ul>
<li>TFF Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TFFP#NASDAQ">TFFP</a>) stock moved upwards by 27.9% to $2.63 during Friday's pre-market session. The company's market cap stands at $9.1 million. </li>
<li>Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) stock rose 12.62% to $69.4. The market value of their outstanding shares is at $36.5 billion. As per the news, the Q3 earnings report came out today. </li>
<li>Nexalin Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXL#NASDAQ">NXL</a>) shares rose 9.31% to $2.35. The market value of their outstanding shares is at $24.8 million. </li>
<li>Citius Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTOR#NASDAQ">CTOR</a>) shares increased by 8.76% to $1.31. The company's market cap stands at $93.4 million. </li>
<li>Actinium Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ATNM#AMEX">ATNM</a>) shares increased by 8.33% to $1.82. The company's market cap stands at $56.7 million. </li>
<li>BioVie (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIVI#NASDAQ">BIVI</a>) shares rose 8.11% to $2.93. The market value of their outstanding shares is at $23.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Monopar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNPR#NASDAQ">MNPR</a>) stock fell 23.9% to $24.85 during Friday's pre-market session. The company's market cap stands at $87.4 million. </li>
<li>Quince Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNCX#NASDAQ">QNCX</a>) stock declined by 15.97% to $1.0. The company's market cap stands at $43.2 million. </li>
<li>Bionomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNOX#NASDAQ">BNOX</a>) stock declined by 14.89% to $0.31. The market value of their outstanding shares is at $4.0 million. </li>
<li>Hepion Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HEPA#NASDAQ">HEPA</a>) shares decreased by 11.01% to $0.65. The company's market cap stands at $3.7 million. </li>
<li>Dogwood Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DWTX#NASDAQ">DWTX</a>) stock fell 10.11% to $4.27. The market value of their outstanding shares is at $5.6 million. </li>
<li>Passage Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PASG#NASDAQ">PASG</a>) shares decreased by 9.91% to $0.58. The market value of their outstanding shares is at $35.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ATNM

BIVI

BNOX

CTOR

DWTX

HEPA

MNPR

PASG

QNCX

TFFP

12 Health Care Stocks Moving In Friday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>TFF Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TFFP#NASDAQ">TFFP</a>) stock moved upwards by 27.9% to $2.63 during Friday's pre-market session. The market value of their outstanding shares is at $9.1 million. </li>
<li>Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) shares increased by 12.62% to $69.4. The market value of their outstanding shares is at $36.5 billion. As per the press release, Q3 earnings came out today. </li>
<li>Nexalin Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXL#NASDAQ">NXL</a>) shares rose 9.31% to $2.35. The company's market cap stands at $24.8 million. </li>
<li>Citius Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTOR#NASDAQ">CTOR</a>) stock rose 8.76% to $1.31. The company's market cap stands at $93.4 million. </li>
<li>Actinium Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ATNM#AMEX">ATNM</a>) stock moved upwards by 8.33% to $1.82. The company's market cap stands at $56.7 million. </li>
<li>BioVie (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIVI#NASDAQ">BIVI</a>) stock increased by 8.11% to $2.93. The company's market cap stands at $23.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Monopar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNPR#NASDAQ">MNPR</a>) shares declined by 23.9% to $24.85 during Friday's pre-market session. The market value of their outstanding shares is at $87.4 million. </li>
<li>Quince Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNCX#NASDAQ">QNCX</a>) stock fell 15.97% to $1.0. The company's market cap stands at $43.2 million. </li>
<li>Bionomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNOX#NASDAQ">BNOX</a>) stock decreased by 14.89% to $0.31. The company's market cap stands at $4.0 million. </li>
<li>Hepion Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HEPA#NASDAQ">HEPA</a>) shares declined by 11.01% to $0.65. The market value of their outstanding shares is at $3.7 million. </li>
<li>Dogwood Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DWTX#NASDAQ">DWTX</a>) stock declined by 10.11% to $4.27. The company's market cap stands at $5.6 million. </li>
<li>Passage Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PASG#NASDAQ">PASG</a>) shares declined by 9.91% to $0.58. The company's market cap stands at $35.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

On Friday, Centene Corporation&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) third-quarter&nbsp;sales of&nbsp;$42.02 billion, up&nbsp;10.5%&nbsp;year-over-year, beating the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of&nbsp;$37.69 billion</a>.
Centene earned an adjusted EPS of $1.62 during the quarter, <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/n41539767/centene-corporation-reports-third-quarter-2024-results" rel="noreferrer noopener">beating the consensus of $1.38</a>.
For the third quarter of 2024, premium and service revenues increased 6% to $36.9 billion, primarily driven by Medicaid rate increases and membership growth in the Marketplace business due to strong product positioning and overall market growth, partially offset by lower Medicaid membership primarily due to redeterminations and recent divestitures in the Other segment.
The Health benefits ratio (HBR) reached 89.2% for the third quarter, up from 87.0% a year ago, primarily driven by higher acuity in Medicaid resulting from the redetermination process Medicare Star rating impacts.
&#8220;Our diversified portfolio has allowed us to successfully navigate a dynamic landscape in the quarter. At the same time, we delivered on fundamentals that carry positive implications for Centene&#8217;s multi-year earnings trajectory, including notable RFP wins, Medicare Stars improvements, and ongoing operational efficiencies,&#8221; said Centene CEO Sarah London.
&#8220;We remain confident in our full-year outlook for adjusted diluted EPS of greater than $6.80 and are well positioned to capture the powerful, long-term growth opportunities we see in government-sponsored healthcare.&#8221;
Centene said total managed care membership increased 2.4% to 28.64 million at the end of the third quarter, compared to 27.97 million a year ago.
Centene&#8217;s enrollment in its &#8220;commercial marketplace&#8221; business grew to 4.50 million members from 3.68 million a year ago.&nbsp;Total Medicaid memberships fell 14.2% to 13.07 million.
Guidance:&nbsp;Centene reaffirms the 2024 adjusted EPS guidance floor of over $6.80 versus a consensus of $6.82.
The company&#8217;s revenue guidance has been updated to&nbsp;$159 billion—$161 billion, compared to the <a target="_blank" href="https://www.benzinga.com/news/earnings/24/07/39984784/health-insurer-centenes-q2-premium-revenue-cushions-fall-in-medicaid-enrollment-raises-annual-outlo" rel="noreferrer noopener">prior guidance of $155.0 billion—$157.0 billion</a> and the consensus of $155.625 billion.
The 2024 HBR is expected to be around 88.3%-88.5%, compared to the high end of the previous guidance range, approximately 87.9%.
Centene increased its 2024 Premium and service revenues guidance range to $143.5 billion—$144.5 billion, compared to its prior guidance of $141 billion—$143 billion.
Price Action: CNC stock is up 13.6% at $70.02 during the premarket session at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/10/41528055/cdc-and-prevention-advisory-panel-backs-expanded-use-of-pfizer-and-mercks-pneumococcal-vaccines" target="_blank" rel="noreferrer noopener">CDC And Prevention Advisory Panel Backs Expanded Use Of Pfizer And Merck&#8217;s Pneumococcal Vaccines</a></li>
</ul>

Large Cap

Guidance

Health Care

Centene Says It Is Positioned To Capture Long-Term Growth In Government-Sponsored Healthcare, Lifts Annual Outlook

WIIM

Centene shares are trading higher after the company reported better-than-expected Q3 financial results.

Centene Expects 2024 Adjusted Diluted EPS Guidance Floor Of Greater Than $6.80 Versus Consensus Of $6.81

Membership increases of 22% in Marketplace and 49% in Medicare Prescription Drug Plans, compared to the third quarter of 2023.

Centene Reported Q3 Health Benefits Ratio Of 89.2%, Total Membership Reached 28.64M

Centene Q3 2024 Adj. EPS $1.62 Beats $1.38 Estimate, Sales $42.023B Beat $37.699B Estimate

Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) is set to give its latest quarterly earnings report on Friday, 2024-10-25. Here's what investors need to know before the announcement.
Analysts estimate that Centene will report an earnings per share (EPS) of $1.42. 
Investors in Centene are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Earnings History Snapshot</h3>
During the last quarter, the company reported an EPS beat by $0.35, leading to a 0.0% drop in the share price on the subsequent day.
Here's a look at Centene's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>2.07</td>
<td>2.08</td>
<td>0.43</td>
<td>1.57</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>2.42</td>
<td>2.26</td>
<td>0.45</td>
<td>2</td>
</tr>
<tr>
<td>Price Change %</td>
<td>8.0%</td>
<td>-2.0%</td>
<td>0.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1729778434_0_0.png" alt="eps graph" />
<h3>Performance of Centene Shares</h3>
Shares of Centene were trading at $59.82 as of October 23. Over the last 52-week period, shares are down 7.51%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<h3>Analysts' Take on Centene</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Centene.
Analysts have given Centene a total of 12 ratings, with the consensus rating being Outperform. The average one-year price target is $90.67, indicating a potential 51.57% upside.
<h3>Analyzing Ratings Among Peers</h3>
In this analysis, we delve into the analyst ratings and average 1-year price targets of Molina Healthcare, HealthEquity and Alignment Healthcare, three key industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>As per analysts' assessments, Molina Healthcare is favoring an Outperform trajectory, with an average 1-year price target of $377.14, suggesting a potential 530.46% upside.</li>
<li>The consensus outlook from analysts is an Outperform trajectory for HealthEquity, with an average 1-year price target of $102.14, indicating a potential 70.75% upside.</li>
<li>Analysts currently favor an Buy trajectory for Alignment Healthcare, with an average 1-year price target of $10.0, suggesting a potential 83.28% downside.</li>
</ul>
<h3>Peers Comparative Analysis Summary</h3>
The peer analysis summary offers a detailed examination of key metrics for Molina Healthcare, HealthEquity and Alignment Healthcare, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Centene</td>
<td>Outperform</td>
<td>5.92%</td>
<td>$4.43B</td>
<td>4.22%</td>
</tr>
<tr>
<td>Molina Healthcare</td>
<td>Outperform</td>
<td>18.65%</td>
<td>$1.21B</td>
<td>6.45%</td>
</tr>
<tr>
<td>HealthEquity</td>
<td>Outperform</td>
<td>23.15%</td>
<td>$204.05M</td>
<td>1.68%</td>
</tr>
<tr>
<td>Alignment Healthcare</td>
<td>Buy</td>
<td>47.34%</td>
<td>$75.97M</td>
<td>-18.86%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Centene ranks in the middle for revenue growth among its peers. It has the highest gross profit margin. Centene's return on equity is lower than two peers but higher than one.
<h3>Discovering Centene: A Closer Look</h3>
Centene is a managed-care organization focused on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 24 million medical members as of June 2023, mostly in Medicaid (67% of membership), the individual exchanges (14%), and Medicare Advantage (6%) plans. The company also serves traditional Medicare users with its Medicare Part D pharmaceutical program.
<h3>Centene's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Centene's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 5.92%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Centene's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 2.88%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Centene's ROE stands out, surpassing industry averages. With an impressive ROE of 4.22%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Centene's ROA stands out, surpassing industry averages. With an impressive ROA of 1.38%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Centene's debt-to-equity ratio surpasses industry norms, standing at 0.64. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<a href="https://www.benzinga.com/quote/CNC/earnings">To track all earnings releases for Centene visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Outlook For Centene

Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) has outperformed the market over the past 15 years by 6.76% on an annualized basis producing an average annual return of 18.69%. Currently, Centene has a market capitalization of $31.54 billion. 
Buying $1000 In CNC: If an investor had bought $1000 of CNC stock 15 years ago, it would be worth $13,066.45 today based on a price of $59.97 for CNC at the time of writing.
<h3>Centene's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729713611_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Centene 15 Years Ago Would Be Worth This Much Today

These ten large-cap stocks were the worst performers in the last week. Are they in your portfolio?
<ol>
<li>NIO Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) stock lost 16.35% last week as U.S.-listed Chinese stocks <a href="https://www.benzinga.com//node/41385461" target="_blank" rel="noreferrer noopener">fell after China&#8217;s September exports</a> missed estimates. China stimulus uncertainty has also weighed on stocks recently.</li>
<li>KLA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLAC#NASDAQ">KLAC</a>) stock dipped 15.58%, probably due to continued weakness following weak guidance from ASML.</li>
<li>Centene Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) shares were down 14.38%. The company will report <a href="https://www.benzinga.com/earnings" target="_blank" rel="noreferrer noopener">third-quarter results on October 25</a>.</li>
<li>Elevance Health shares dipped 14.17% after analysts cut forecasts <a href="https://www.benzinga.com//node/41405601" target="_blank" rel="noreferrer noopener">following third-quarter earnings</a>.</li>
<li>ASML Holding N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>) shares tumbled 13.97% after the company accidentally released earnings a day ahead of schedule and <a href="https://www.benzinga.com//node/41358875" target="_blank" rel="noreferrer noopener">cut its 2025 sales forecast</a>.</li>
<li>Temu parent PDD Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>) stock fell 13.91%, as did U.S.-listed Chinese stocks <a href="https://www.benzinga.com//node/41316058" target="_blank" rel="noreferrer noopener">after China&#8217;s September exports</a> missed estimates. China stimulus uncertainty has also weighed on stocks recently.</li>
<li>Molina Healthcare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) shares were down 12.24%, probably in sympathy with Elevance Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>), which reported third-quarter earnings miss and issued soft FY24 guidance.</li>
<li>Lam Research Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>) stock dived 12.12%, probably in sympathy with Taiwan Semiconductor Manufacturing Company Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>), which reported better-than-expected <a href="https://www.benzinga.com//node/41377745" target="_blank" rel="noreferrer noopener">earnings and issued strong guidance</a>.</li>
<li>Erie Indemnity Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERIE#NASDAQ">ERIE</a>) fell 9.92% last week after Spruce Point Management <a href="https://www.sprucepointcap.com/research/erie-indemnity-company" target="_blank" rel="noreferrer noopener">issued a short-sell report</a> on the stock. The company was under pressure due to Category 5 Hurricane Milton.</li>
<li>CVS Health Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) stock fell 9.44% last week after the company <a href="https://www.benzinga.com//node/41399396" target="_blank" rel="noreferrer noopener">cut its Q3 outlook</a>.</li>
</ol>
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/10/41418879/coinbase-united-airlines-and-sofi-tech-are-among-top-11-large-cap-gainers-last-week-oct-14-18-are-" target="_blank" rel="noreferrer noopener">Coinbase, United Airlines And Sofi Tech Are Among Top 11 Large Cap Gainers Last Week (Oct 14-18): Are The Others In Your Portfolio?</a></li>
</ul>
Photo via Shutterstock

ASML

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

ERIE

KLAC

LRCX

Citigourp Global Markets 2% Protected Notes Linked To The Djia

NIO, ASML, And CVS Health Are Among Top 10 Large Cap Losers Last Week (Oct 14-18): Are The Others In Your Portfolio?

Deep-pocketed investors have adopted a bearish approach towards Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in CNC usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 21 extraordinary options activities for Centene. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 19% leaning bullish and 76% bearish. Among these notable options, 15 are puts, totaling $4,405,390, and 6 are calls, amounting to $307,439.
<h3>What's The Price Target?</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $55.0 to $67.5 for Centene during the past quarter. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Centene's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Centene's whale trades within a strike price range from $55.0 to $67.5 in the last 30 days. 
<h3>Centene 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729197113_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CNC</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$3.4</td>
<td>$3.0</td>
<td>$3.3</td>
<td>$66.00</td>
<td>$1.6M</td>
<td>11.9K</td>
<td>8.9K</td>
</tr>
<tr>
<td>CNC</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/29/24</td>
<td>$1.1</td>
<td>$0.9</td>
<td>$0.95</td>
<td>$55.00</td>
<td>$730.0K</td>
<td>0</td>
<td>7.6K</td>
</tr>
<tr>
<td>CNC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$3.3</td>
<td>$3.2</td>
<td>$3.3</td>
<td>$66.00</td>
<td>$330.1K</td>
<td>11.9K</td>
<td>1.0K</td>
</tr>
<tr>
<td>CNC</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$3.2</td>
<td>$2.5</td>
<td>$3.0</td>
<td>$66.00</td>
<td>$300.0K</td>
<td>11.9K</td>
<td>11.9K</td>
</tr>
<tr>
<td>CNC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$3.4</td>
<td>$2.95</td>
<td>$3.0</td>
<td>$66.00</td>
<td>$273.6K</td>
<td>11.9K</td>
<td>3.0K</td>
</tr>
</tbody>
</table>

<h3>About Centene</h3>
Centene is a managed-care organization focused on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 24 million medical members as of June 2023, mostly in Medicaid (67% of membership), the individual exchanges (14%), and Medicare Advantage (6%) plans. The company also serves traditional Medicare users with its Medicare Part D pharmaceutical program.
Having examined the options trading patterns of Centene, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Where Is Centene Standing Right Now?</h3>
<ul>
<li>With a volume of 14,571,018, the price of CNC is down -8.8% at $63.2. </li>
<li>RSI indicators hint that the underlying stock may be oversold.</li>
<li>Next earnings are expected to be released in 8 days.</li>
</ul>
<h3>What Analysts Are Saying About Centene</h3>
Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $90.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Cantor Fitzgerald has revised its rating downward to Overweight, adjusting the price target to $90. 
&#x2A; An analyst from Cantor Fitzgerald has revised its rating downward to Overweight, adjusting the price target to $90. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Centene with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Analyst Ryan Langston from TD Cowen maintained a Buy rating on Centene (CNC – Research Report) and decreased the price target to $80.00 from $89.00...

Centene's Promising Financial Outlook: Buy Rating Affirmed Despite Price Target Adjustment

Barclays analyst Andrew Mok lowered the firm's price target on Centene (CNC) to $91 from $97 and keeps an Overweight rating on the shares post the ...

Centene price target lowered to $91 from $97 at Barclays

Bernstein analyst Lance Wilkes has reiterated their bullish stance on CNC stock, giving a Buy rating yesterday. Lance Wilkes's rating is based on C...

Centene's Strong Performance and Growth Prospects Support Buy Rating Despite Political Risks

Call overwriting and call buying opportunities within the Russell 1000 – JPM

Stocks with cheap implied volatility – JPM

Bullish option flow detected in Centene (CNC) with 11,552 calls trading, 2.0x expected, and implied vol increasing over 4 points to 42.61%. Dec-24 ...

Centene call volume above normal and directionally bullish

Wells Fargo lowered the firm's price target on Centene (CNC) to $90 from $91 and keeps an Overweight rating on the shares. Following the bulk of ea...

Centene price target lowered to $90 from $91 at Wells Fargo

Wells Fargo analyst Steve Baxter maintained a Buy rating on Centene (CNC – Research Report) yesterday and set a price target of $90.00. The company...

Centene (CNC) Receives a Buy from Wells Fargo

Unusual total active option classes on open include: Public Service Enterprise Group (PEG), Ericsson (ERIC), PowerShares DB US Dollar Index Bullish...

Comments

Centene

Centene (CNC) オプション

Centene (NYSE:CNC) 株価情報, オプションチェーン

ニュース

パートナーシップ

ベンジンガ・グローバル